Successful oral desensitization to trimethoprim-sulfamethoxazole in acquired immune deficiency syndrome

Annals of Allergy, Asthma and Immunology

Volumn 77, Issue 5, 1996, Pages 394-400

  Kalanadhabhatta, V ^a,b   Muppidi, D ^a   Sahni, H ^a   Robles, A ^a   Kramer, M ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b Box 50 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; COTRIMOXAZOLE; PREDNISONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANGIONEUROTIC EDEMA; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; CLINICAL PROTOCOL; DESENSITIZATION; DRUG ERUPTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MALE; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 0029730769     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)63338-8     Document Type: Article

References (44)

1. U.S. Public Health Service Task on antipneumocystis prophylaxis in patients with HIV: Recommendations for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. J Acquired Immune Deficiency Syndromes 1993;6:46-55.
2. Fischl MA, Dickinson GM, LaVoie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988;259: 1185-9.
3. Schneider M, Hoepelman A, Schattenkerk JK, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992;327: 1836-41.
4. Hardy WD, Feinberg J, Finkelstein D, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome AIDS clinical trials group protocol 021. N Engl J Med 1992;327:1842-8.
5. Carr A, Tindall B, Brew NJ, et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992;117:106-11.
6. Stein DS, Stevens RC, Terry D, et al. Use of low-dose trimethoprim-sulfamethoxazole thrice weekly for primary and secondary prophylaxis of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Antimicrobial Agents Chemother 1991;35:1705-9.
7. Martin MA, Cox PH, Beck K, et al. A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Arch Intern Med 1992; 152:523-8.
8. Armstrong D, Gold JWM, Dryjansky J, et al. Treatment of infections in patients with the acquired immune deficiency syndrome. Ann Intern Med 1985;103:738-43.
9. Centers for Disease Control. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human deficiency virus. MMWR 1992;41:RR4:1-11.
10. Jules-Elysee KM, Stover DE, Zaman MB, et al. Aerosolized pentamidine: effect on diagnosis and presentation of Pneumocystis carinii pneumonia. Ann Intern Med 1990;112:750-7.
11. Sepkowitz K, Telzak EE, Gold JWM, et al. Pneumothorax in AIDS. Ann Intern Med 1991;114:455-9.
12. Raviglione MC. Extrapulmonary pneumocystosis: the first 50 cases. Rev Infec Dis 1990;12:1127-38.
13. Ena J, Amador C, Pasquau F, et al. Once-a-month administration of intravenous pentamidine to patients infected with human immunodeficiency virus as prophylaxis for Pneumocystis carinii pneumonia. Clin Infec Dis 1994;18:901-4.
14. Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 1994;120:932-44.
15. Jorde UP, Horowitz HW, Wormser GP. Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulfamethoxazole-interferant. HIV-infected individuals. AIDS 1993;7:355-9.
16. Metroka CE, McMechan MF, Andrada R, et al. Failure of prophylaxis with dapsone in patients taking dideoxyinosine. [Letter]. N Engl J Med 1991; 325:10:737.
17. Kay R, DuBois R. Clindamycin/ primaquine therapy and secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS. Southern Med J 1990;83:403-4.
18. Putterman C, Rahav G, Shalit M, Rubinow A. "Treating through" hypersensitivity to co-trimoxazole in AIDS patients. [Letter]. Lancet 1990;336:52.
19. Carr A, Penny R, Cooper D. Efficacy and safety of rechallenge with low dose trimethoprim-sulfamethoxazole in previously hypersensitive HIV-infected patients. AIDS 1993;7:65-71.
20. Arnold AP, Guglielmo J, Hollander H. Severe hypersensitivity reaction upon rechallenge with trimethoprim-sulfamethoxazole in a patient with AIDS. Drug Intell Clin Pharm. 1988;22:43-5.
21. Cohn LD, Penley AK, Judson NF, et al. The acquired immune deficiency syndrome and a trimethoprim-sulfamethoxazole adverse reaction. [Letter]. Ann Intern Med 1984;100:311.
22. Chanock JS, Luginbuhl ML, McIntosh K, Lipshultz ES. Life threatening reaction to trimethoprim-sulfamethoxazole in pediatric human immunodeficiency virus infection. Pediatr 1994;93: 519-20.
23. Finegold I. Oral desensitization to trimethoprim-sulfamethoxazole in a patient with acquired immune deficiency syndrome. J Allergy Clin Immunol 1986;78:905-8.
24. Kreuz W, Gungor T, Lotz CHR, et al. "Treating Through" hypersensitivity Io co-trimaxozole in children with HIV infection [Letter-Comment]. Lancet 1990;336:508-9.
25. Tenant-Flowers M, Boyle MJ, Carey D, et al. Sulfa desensitization in patients with AIDS and cerebral toxoplasmosis. AIDS 1991;5:311-5.
26. Kletzel M, Beck S, Elser J, et al. Trimethoprim-sulfamethoxazole oral desensitization in hemophiliacs infected with human immunodeficiency virus with a history of hypersensitivity reactions. Am J Dis Child 1991;145: 1428-9.
27. White MW, Haddad HZ, Brunner E, Sainz C. Desensitization to trimethoprim-sulfamethoxazole in patients with acquired immune deficiency syndrome and Pneumocystis carinii pneumonia. Ann Allergy 1989; 62:177-9.
28. de la Hoz Caballer B, Fernandez-Rivas M, Fraj Lazaro J, et al. Management of sulfadiazine allergy in patients with acquired immunodeficiency syndrome. J Allergy Clin Immunol 1991;88: 137-8.
29. Absar N, Daneshvar H, Beall G. Desensitization to trimethoprim-surfamethoxazole in HIV-infected patients. J Allergy Clin Immunol 1994;93: 1001-5.
30. Safrin, S. Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Semin Respir Infec 1993;8:96-103.
31. Greenberger PA, Patterson R. Management of drug allergy in patients with acquired immunodeficiency syndrome. J Allergy Clin Immunol 1987; 79:484-8.
32. 2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14(3):107-11.
33. Wilson RA. The liver - its role in drug biotransformation and as a target of immunologic injury. Immunol Allergy Clin N Am 1991;11:555-74.
34. Kaplowitz N, Aw TY, Simon FR, et al. Drug-induced hepatotoxicity. Ann Intern Med 1986;104:826-39.
35. Poizot-Martin I, Mercier P, Coso D, et al. HLA typing in HIV infected Caucasian patients with sulfonamide allergy. Int Conf AIDS Jun 6-11, 1993;9(1): 450 (Abstract # PO-B20-1889).
36. Bayard PJ, Berger TG, Jacobson MA. Drug hypersensitivity reactions and human immunodeficiency virus disease. J. AIDS 1992;5:1237-57.
37. Gordin FM, Simon GL, Wofsky CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984;100:495-9.
38. Gruchalla R, Sullivan TJ. Detection of human IgE to sulfamethoxazole by skin testing with sulfamethoxazole poly 1-tyrosine. J Allergy Clin Immunol 1991;88:784-92.
39. Riedor MJ, Shear NH, Kanee A, et al. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharm Ther 1991;49:13-7.
40. Shor MR, Suchar C, Lockey RF. Anaphylactic shock induced by oral desensitization to trimethoprim-sulfamethoxazole. [Abstract]. J Allergy Clin. Immunol. 1986;77:133.
41. Sullivan TJ. Drug allergy. Middleton E, Jr, Reed CE, Ellis EF, et al (eds). Allergy - principles and practice, vol II. Fourth edition. St. Louis: Mosby-Yearbook Inc. 1993;1726-46.
42. Friedman A, Weiner HL. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc Natl Acad Sci 1994;91: 6688-92.
43. Casale L, Gold H, Schechter C, et al. Decreased efficacy of inhaled pentamidine in the prevention of Pneumocystis carinii pneumonia among HIV-infected patients with severe immunodeficiency. Chest 1993;103: 342-4.
44. Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:693-9.